We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HIV/AIDS
ImQuest Receives Two Year Phase 2 SBIR Grant to Develop Pyrimidinedione Product as an Anti-HIV Topical Microbicide
August 13th, 2008
ImQuest BioSciences announced the successful acquisition of funding from the National Institute of Allergy and Infectious Disease (NIAID/NIH) to support the development of pyrimidinedione inhibitors as topical microbicides to prevent the sexual transmission of HIV. The two year Small Business Innovative Research (SBIR) grant provides funding for the continued development of the dual-acting pyrimidinedione molecules which effectively inhibit two critical steps in the HIV replication pathway important for a microbicide. The research to be performed will enable ImQuest scientist's to comparatively evaluate their most potent lead preventative agents and define the most potent microbicide...
